Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$16.57 USD

16.57
466,978

-0.03 (-0.18%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session

Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.

    Pacira Pharmaceuticals (PCRX) Down 4.7% Since Earnings Report: Can It Rebound?

    Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Heron's Pain Candidate Meets Endpoint in Pivotal Studies

      Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.

        Pacira (PCRX) Posts Earnings in Q4, Revenues in Line

        Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.

          Implied Volatility Surging for Pacira (PCRX) Stock Options

          Pacira (PCRX) needs investors to pay close attention to the stock based on moves in the options market lately.

            Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?

            Pacira (PCRX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee

              Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.

                Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates

                Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.

                  Pacira Pharmaceuticals Focuses on Exparel's Label Expansion

                  Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.

                    Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss

                    Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.

                      Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?

                      Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Pacira Focuses on Lead Candidate Exparel's Label Expansion

                        We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.

                          Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound?

                          Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Why Earnings Season Could Be Great for Pacira Pharmaceuticals (PCRX)

                            Investors are always looking for stocks that are poised to beat at earnings season and Pacira Pharmaceuticals, Inc. (PCRX) may be one such company.

                              Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?

                              Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.

                                Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?

                                Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.

                                  Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?

                                  Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.

                                    Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?

                                    Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.

                                      Universal Health (UHS) Q4 Earnings: What's in the Cards?

                                      Universal Health Services, Inc. (UHS) will release fourth-quarter 2016 results on Feb 28, after the market closes. Last quarter, the company posted a negative earnings surprise of 4.19%.

                                        Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

                                        Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.

                                          Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?

                                          Arena Pharmaceuticals, Inc. (ARNA) is expected to report fourth-quarter 2016 results next month.

                                            Keryx (KERX) Q4 Earnings: What's in Store for the Stock?

                                            Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.

                                              Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?

                                              Tenet Healthcare Corporation (THC) will release fourth-quarter 2016 results on Feb 27, after the market closes. Let's see how things are shaping up for this announcement.

                                                Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?

                                                Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter

                                                  Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?

                                                  Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.